SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-026724
Filing Date
2021-05-12
Accepted
2021-05-12 06:19:26
Documents
59
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q inzy-10q_20210331.htm 10-Q 1501139
2 EX-31.1 inzy-ex311_6.htm EX-31.1 20597
3 EX-31.2 inzy-ex312_8.htm EX-31.2 20611
4 EX-32.1 inzy-ex321_7.htm EX-32.1 9605
5 EX-32.2 inzy-ex322_9.htm EX-32.2 9657
  Complete submission text file 0001564590-21-026724.txt   5969173

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT inzy-20210331.xml EX-101.INS 1306306
7 XBRL TAXONOMY EXTENSION SCHEMA inzy-20210331.xsd EX-101.SCH 40033
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inzy-20210331_cal.xml EX-101.CAL 40696
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inzy-20210331_def.xml EX-101.DEF 135991
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20210331_lab.xml EX-101.LAB 365602
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20210331_pre.xml EX-101.PRE 275691
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 21913377
SIC: 2834 Pharmaceutical Preparations